Skip to main content
ROVI Subsidiaries
Spain
Germany
France
Italy
Poland
Portugal
United Kingdom
Language
Spanish
Spanish
English
English
English
Español
Home
ROVI
History
Group structure
Business units
International expansion
Strategy
Licenses
Contact
Products
Prescription Pharmaceuticals
Hospital Products
Manufacturing
CDMO
Own product Manufacturing
R&D
Shareholders and Investors
The share
Investor's Calendar
News
Financial and Business Information
CMNV Communications
ESG
Corporate Governance
Telematic assistance access
Prior Registration On-Line Attendance
On-Line Attendance
Sustainability
Responsible governance
Commitment to people
Environmental Commitment
Ethics Channel
Media
FAQS
News
ROVI up to date
Contact
Work with Us
TELEMATIC ASSISTANCE ACCESS
Home
News
Results of the final analysis of the ABEL Phase II clinical trial
Wed, 19/10/2011 - 09:13
0 min
Download related document
Select rating
Give Results of the final analysis of the ABEL Phase II clinical trial 1/5
Give Results of the final analysis of the ABEL Phase II clinical trial 2/5
Give Results of the final analysis of the ABEL Phase II clinical trial 3/5
Give Results of the final analysis of the ABEL Phase II clinical trial 4/5
Give Results of the final analysis of the ABEL Phase II clinical trial 5/5
No votes yet
Related
First half 2022 results press release
ROVI REPORTS OPERATING REVENUE GROWTH OF 31% AND NET PROFIT GROWTH OF 58% Operating revenue increased by 31% to 380.4...
3 min
27/07/2022
The European Investment Bank and ROVI spur innovation in the Spanish...
Madrid, 19th July 2022 The European Investment Bank (EIB) is providing Laboratorios Farmacéuticos Rovi (ROVI) with a new EUR 50 million...
4 min
19/07/2022
First quarter 2022 results press release
ROVI REPORTS OPERATING REVENUE GROWTH OF 57% AND NET PROFIT GROWTH OF 123% • Operating revenue increased by 57% to 205.6 million euros...
2 min
11/05/2022
See More
Email
Facebook
Twitter
LinkedIn